Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT

NCT04304482 is registered in ClinicalTrials.gov with Anavex Life Sciences Corp. as lead sponsor.

NCT NCT04304482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04304482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT
Lead sponsor
Anavex Life Sciences Corp.
Phase
Phase 2/3
Overall status
Completed
Start date
July 1, 2020
Completion date
June 30, 2023
Enrollment
92 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome